These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 28915395)

  • 1. Effects of polymyxin B hemoperfusion on hemodynamics and prognosis in septic shock patients.
    Lee CT; Tu YK; Yeh YC; Chang T; Shih PY; Chao A; Huang HH; Cheng YJ; Yeh YC;
    J Crit Care; 2018 Feb; 43():202-206. PubMed ID: 28915395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct hemoperfusion with a polymyxin B column versus vasopressin for gram negative septic shock: a matched cohort study of the effect on survival.
    Sawa N; Ubara Y; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hoshino J; Suwabe T; Uchida N; Wake A; Taniguchi S; Takaichi K
    Clin Nephrol; 2013 Jun; 79(6):463-70. PubMed ID: 23253903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial.
    Cruz DN; Antonelli M; Fumagalli R; Foltran F; Brienza N; Donati A; Malcangi V; Petrini F; Volta G; Bobbio Pallavicini FM; Rottoli F; Giunta F; Ronco C
    JAMA; 2009 Jun; 301(23):2445-52. PubMed ID: 19531784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial.
    Payen DM; Guilhot J; Launey Y; Lukaszewicz AC; Kaaki M; Veber B; Pottecher J; Joannes-Boyau O; Martin-Lefevre L; Jabaudon M; Mimoz O; Coudroy R; Ferrandière M; Kipnis E; Vela C; Chevallier S; Mallat J; Robert R;
    Intensive Care Med; 2015 Jun; 41(6):975-84. PubMed ID: 25862039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying Septic Shock Populations Benefitting From Polymyxin B Hemoperfusion: A Prospective Cohort Study Incorporating a Restricted Cubic Spline Regression Model.
    Nakata H; Yamakawa K; Kabata D; Umemura Y; Ogura H; Gando S; Shintani A; Shiraishi A; Saitoh D; Fujishima S; Mayumi T; Kushimoto S; Abe T; Shiino Y; Nakada TA; Tarui T; Hifumi T; Otomo Y; Okamoto K; Kotani J; Sakamoto Y; Sasaki J; Shiraishi SI; Takuma K; Tsuruta R; Hagiwara A; Masuno T; Takeyama N; Yamashita N; Ikeda H; Ueyama M; Fujimi S;
    Shock; 2020 Nov; 54(5):667-674. PubMed ID: 32195922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential survival benefit of polymyxin B hemoperfusion in patients with septic shock: a propensity-matched cohort study.
    Nakamura Y; Kitamura T; Kiyomi F; Hayakawa M; Hoshino K; Kawano Y; Yamasaki R; Nishida T; Mizunuma M; Ishikura H;
    Crit Care; 2017 Jun; 21(1):134. PubMed ID: 28592318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rescue therapy with polymyxin B hemoperfusion in high-dose vasopressor therapy refractory septic shock.
    Monti G; Terzi V; Calini A; Di Marco F; Cruz D; Pulici M; Brioschi P; Vesconi S; Fumagalli R; Casella G
    Minerva Anestesiol; 2015 May; 81(5):516-25. PubMed ID: 25319136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of polymyxin B-immobilized fiber hemoperfusion for patients with septic shock caused by Gram-negative bacillus infection.
    Saito N; Sugiyama K; Ohnuma T; Kanemura T; Nasu M; Yoshidomi Y; Tsujimoto Y; Adachi H; Koami H; Tochiki A; Hori K; Wagatsuma Y; Matsumoto H
    PLoS One; 2017; 12(3):e0173633. PubMed ID: 28358803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PMX endotoxin removal in the clinical practice: results from the EUPHAS trial.
    Antonelli M; Fumagalli R; Cruz DN; Brienza N; Giunta F
    Contrib Nephrol; 2010; 167():83-90. PubMed ID: 20519902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymyxin B hemoperfusion in coronavirus disease 2019 patients with endotoxic shock: Case series from EUPHAS2 registry.
    De Rosa S; Cutuli SL; Ferrer R; Antonelli M; Ronco C;
    Artif Organs; 2021 Jun; 45(6):E187-E194. PubMed ID: 33377184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of polymyxin B hemoperfusion therapy on high endotoxin activity level patients after successful infection source control: a prospective cohort study.
    Lee WY; Kim HJ; Kim EY
    Sci Rep; 2021 Dec; 11(1):24132. PubMed ID: 34916567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial.
    Klein DJ; Foster D; Walker PM; Bagshaw SM; Mekonnen H; Antonelli M
    Intensive Care Med; 2018 Dec; 44(12):2205-2212. PubMed ID: 30470853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymyxin B-immobilised haemoperfusion and mortality in critically ill patients with sepsis/septic shock: a protocol for a systematic review and meta-analysis.
    Fujii T; Ganeko R; Kataoka Y; Featherstone R; Bagshaw SM; Furukawa TA
    BMJ Open; 2016 Nov; 6(11):e012908. PubMed ID: 27872122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary liver-type fatty acid-binding protein in septic shock: effect of polymyxin B-immobilized fiber hemoperfusion.
    Nakamura T; Sugaya T; Koide H
    Shock; 2009 May; 31(5):454-9. PubMed ID: 18838948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Effects of Polymyxin B Hemoperfusion in Patients With Septic Shock Caused by Urinary Tract Infection.
    Suzuki Y; Kojika M; Sato H; Inoue Y; Endo S
    Ther Apher Dial; 2019 Feb; 23(1):80-85. PubMed ID: 30209889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis.
    Fujii T; Ganeko R; Kataoka Y; Furukawa TA; Featherstone R; Doi K; Vincent JL; Pasero D; Robert R; Ronco C; Bagshaw SM
    Intensive Care Med; 2018 Feb; 44(2):167-178. PubMed ID: 29204670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial.
    Dellinger RP; Bagshaw SM; Antonelli M; Foster DM; Klein DJ; Marshall JC; Palevsky PM; Weisberg LS; Schorr CA; Trzeciak S; Walker PM;
    JAMA; 2018 Oct; 320(14):1455-1463. PubMed ID: 30304428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Extended Duration of Polymyxin B-Immobilized Fiber Column Direct Hemoperfusion on Hemodynamics, Vasoactive Substance Requirement, and Pulmonary Oxygenation in Patients with Sepsis: An Observational Study.
    Mitaka C; Kusao M; Kawagoe I; Satoh D; Iba T; Ronco C
    Blood Purif; 2022; 51(1):62-69. PubMed ID: 33910191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A longer duration of polymyxin B-immobilized fiber column hemoperfusion improves pulmonary oxygenation in patients with septic shock.
    Mitaka C; Tsuchida N; Kawada K; Nakajima Y; Imai T; Sasaki S
    Shock; 2009 Nov; 32(5):478-83. PubMed ID: 19295483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of polymyxin B-immobilized hemoperfusion against sepsis and septic shock: A systematic review and meta-analysis.
    Li X; Liu C; Mao Z; Qi S; Song R; Zhou F
    J Crit Care; 2021 Jun; 63():187-195. PubMed ID: 33012579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.